Journal Watch · Cell · 2026

FOCAS: Transcriptome-wide screening of individual m<sup>6</sup>A sites functionally dissects epitranscriptomic control of gene expression in cancer.

Overall, this study established a powerful, unbiased approach for the functional dissection of m<sup>6</sup>A, advancing the understanding of its complexity and therapeutic relevance in cancers.

Zhang X, Zhang Y, Liu X et al.Cell3 min readPharma relevance 70/100

DOI: 10.1016/j.cell.2025.11.037PMID: 41478283Study type: in-vitro / cell study

TL;DR

Overall, this study established a powerful, unbiased approach for the functional dissection of m<sup>6</sup>A, advancing the understanding of its complexity and therapeutic relevance in cancers.

Key findings

  • We further uncovered universal and cell-type-specific m<sup>6</sup>A patterns, with unique sites enriched in ncRNAs and universal ones in transcription-related genes.
  • In SMMC-7721 cells, we identified m<sup>6</sup>A-regulated transcriptional networks that demonstrated extensive epitranscriptome-transcriptome crosstalk.
  • Overall, this study established a powerful, unbiased approach for the functional dissection of m<sup>6</sup>A, advancing the understanding of its complexity and therapeutic relevance in cancers.

What they did

Applying FOCAS to four human cancer cell lines identified 4,475 m<sup>6</sup>A-regulated genes influencing cell fitness via both mRNAs and non-coding RNAs (ncRNAs), many of which are newly linked to cancer and exhibit dynamic developmental expression. FOCAS uncovered context-dependent and reader-specific effects of m<sup>6</sup>A within the same gene, revealing its intricate regulatory logic.

Full abstract (original)

Background: Although N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) is a pervasive RNA modification essential for gene regulation, dissecting the functions of individual m<sup>6</sup>A sites remains technically challenging. To overcome this, we developed functional m<sup>6</sup>A sites detection by CRISPR-dCas13b-FTO screening (FOCAS), a CRISPR-dCas13b-based platform enabling high-throughput, site-specific functional screening of m<sup>6</sup>A.

What they did: Applying FOCAS to four human cancer cell lines identified 4,475 m<sup>6</sup>A-regulated genes influencing cell fitness via both mRNAs and non-coding RNAs (ncRNAs), many of which are newly linked to cancer and exhibit dynamic developmental expression. FOCAS uncovered context-dependent and reader-specific effects of m<sup>6</sup>A within the same gene, revealing its intricate regulatory logic.

Results & conclusions: We further uncovered universal and cell-type-specific m<sup>6</sup>A patterns, with unique sites enriched in ncRNAs and universal ones in transcription-related genes. In SMMC-7721 cells, we identified m<sup>6</sup>A-regulated transcriptional networks that demonstrated extensive epitranscriptome-transcriptome crosstalk. Overall, this study established a powerful, unbiased approach for the functional dissection of m<sup>6</sup>A, advancing the understanding of its complexity and therapeutic relevance in cancers.

Abstract © the authors / Cell (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.cell.2025.11.037 · PubMed 41478283.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology, gene editing — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology · gene editing

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Cell study find?

Overall, this study established a powerful, unbiased approach for the functional dissection of m<sup>6</sup>A, advancing the understanding of its complexity and therapeutic relevance in cancers.

What type of study is this?

It is a in-vitro / cell study, published in Cell in 2026. Applying FOCAS to four human cancer cell lines identified 4,475 m<sup>6</sup>A-regulated genes influencing cell fitness via both mRNAs and non-coding RNAs (ncRNAs), many of which are newly linked to cancer and exhibit dynamic developmental expression.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.cell.2025.11.037. PubMed ID: 41478283. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zhang X, Zhang Y, Liu X et al.. FOCAS: Transcriptome-wide screening of individual m&lt;sup&gt;6&lt;/sup&gt;A sites functionally dissects epitranscriptomic control of gene expression in cancer.. Cell (2026). DOI: 10.1016/j.cell.2025.11.037.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/focas-transcriptome-wide-screening-of-individual-m-lt-sup-gt-6-lt-sup-gt-511037/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides